TILT Biotherapeutics
Founded Year
2013Stage
Grant - II | AliveTotal Raised
$39.11MLast Raised
$2.25M | 1 mo agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+30 points in the past 30 days
About TILT Biotherapeutics
TILT Biotherapeutics provides oncolytic immunotherapy services. The company develops oncolytic viruses that enhance t-cell therapies for cancer treatment. The company was founded in 2013 and is based in Helsinki, Finland.
Missing: TILT Biotherapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: TILT Biotherapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing TILT Biotherapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
TILT Biotherapeutics is included in 3 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
TILT Biotherapeutics Patents
TILT Biotherapeutics has filed 5 patents.
The 3 most popular patent topics include:
- Biotechnology
- Monoclonal antibodies
- Clusters of differentiation
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/17/2016 | 11/1/2022 | Monoclonal antibodies, Immunology, Autoimmune diseases, Experimental cancer drugs, Immune system | Grant |
Application Date | 3/17/2016 |
|---|---|
Grant Date | 11/1/2022 |
Title | |
Related Topics | Monoclonal antibodies, Immunology, Autoimmune diseases, Experimental cancer drugs, Immune system |
Status | Grant |
Latest TILT Biotherapeutics News
Feb 7, 2023
HELSINKI--(BUSINESS WIRE)--TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces the final close of its EUR 22 million (approximately USD 23.8 million) round. This follows on from the first close of EUR 10 million in June 2022. The financing was led by Finland’s Lifeline Ventures, an early-stage venture capital firm founded by serial entrepreneurs. The funding will be used to advance to Phase II the company’s combination trials which us
TILT Biotherapeutics Frequently Asked Questions (FAQ)
When was TILT Biotherapeutics founded?
TILT Biotherapeutics was founded in 2013.
Where is TILT Biotherapeutics's headquarters?
TILT Biotherapeutics's headquarters is located at Tukholmankatu 8 B, Helsinki.
What is TILT Biotherapeutics's latest funding round?
TILT Biotherapeutics's latest funding round is Grant - II.
How much did TILT Biotherapeutics raise?
TILT Biotherapeutics raised a total of $39.11M.
Who are the investors of TILT Biotherapeutics?
Investors of TILT Biotherapeutics include EIC Accelerator , European Innovation Council, Lifeline Ventures, Finnish Industry Investment, Horizon 2020 and 5 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.